青春期前特发性矮小患儿生长激素治疗效应的相关因素分析

连群; 李伶俐

中国儿童保健杂志 ›› 2013, Vol. 21 ›› Issue (5) : 461-463.

连群,李伶俐

作者信息 +

Effect of recombinant human growth hormone therapy in prepuberty children with idiopathic short stature and analysis of the influencing factors.

LIAN Qun,LI Ling-li.

Author information +

文章历史 +

摘要

目的观察基因重组人生长激素(recombinant human growth hormone,rhGH)治疗青春期前特发性矮小(idiopathic short stature,ISS)患儿第一年生长速率(growth velouty,GV)的疗效及影响因素。方法青春期前ISS患儿共42例,以rhGH治疗后第一年GV为评价指标,探讨与性别、治疗前年龄(CA)、治疗前身高标准差积分(HtSDS)、治疗前体重指数标准差积分(BMI SDS)、父亲HtSDS、母亲HtSDS、治疗前GV、生长激素(growth hormone,GH)峰值、治疗前骨龄(BA)等9个因素的相关性。结果本次研究中42例ISS患儿经rhGH治疗后第一年GV均有所改善,治疗前CA是影响ISS患儿治疗第一年GV的独立因素。结论 ISS患儿采用rhGH治疗的年龄宜早。

Abstract

Objective To observe growth velocity and influencing factors for first-year of recombinant human growth hormone(rhGH)in treating prepuberty children with idiopathic short stature(ISS). Methods Forty-two prepubertal ISS children were treated with rhGH for at least one year.The relationships between gender,age at baseline,height standard deviation score pretreatment,Body Mass Index standard deviation score pretreatment,height standard deviation score of father,height standard deviation score of mother,growth velocity pretreatment,bone age pretreatment and the first year growth velocity were analyzed with correlation analysis. Results rhGH treatment improved all the 42 patients' the first year GV of ISS children in this study.Age at baseline is the independent influence factor on the first year GV. Conclusion rhGH-Treatment for ISS should be performed as young as possible.

导出引用

连群,李伶俐. 青春期前特发性矮小患儿生长激素治疗效应的相关因素分析[J]. 中国儿童保健杂志. 2013, 21(5): 461-463

LIAN Qun,LI Ling-li.. Effect of recombinant human growth hormone therapy in prepuberty children with idiopathic short stature and analysis of the influencing factors.[J]. Chinese Journal of Child Health Care. 2013, 21(5): 461-463

中图分类号： R725.8

参考文献

[1] Consensus statement on the diagnosis and treatment of children with idiopathic short stature:a summary of the Growth Hormone Research Society,the Lawson Wilkins Pediatric Endocrine Society,and the European Society for Paediatric Endocrinology Workshop[J].Clin Endocrinol Metab,2008,93(11):4210-4217.
[2] 李辉.中国0~18岁儿童青少年生长图表[M].1版.上海:第二军医大学出版社,2009,12.
[3] Pedicelli S,Peschiaroli E,Violi E,et al.Controversies in the definition and treatment of idiopathic short stature(ISS)[J].Clin Res Pediatr Endo crinol,2009,1(3):105-115.
[4] Deodati A,Cianfarani S.Impact of growth hormone therapy on adult height of children with idiopathic short stature:systematic review[J].BMJ,2011,11:342.
[5] Ranke MB,Lindberg A,Price DA,et al.Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature[J].Horm Res,2007,68(2):53-62.
[6] Bakker B,Frane J,Anhalt H,et al.Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children[J].Clin Endocrinol Metab,2008,93(2):352-357.
[7] 武华红,李辉,孙淑英.重组人生长激素治疗特发性矮小12个月疗效评估[J].中国循证儿科杂志,2012,7(1):63-67.
[8] Ross J,Lee PA,Gut R,et al.Factors influencing the one-and two-year growth response in children treated with growth hormone:analysis from an observational study[J].Int J Pediatr Endocrinol,2010,4946-4956.